---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-21-000052"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:48:25.129255+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Net loss $17.4M in Q3; cash $290.2M; SL-172154/SL-279252 Phase 1 data; Takeda deal terminated

## Summary
- Net loss $17.4M ($0.41/share) vs $11.8M ($1.54/share) in Q3 2020; cash $290.2M, down from $335.4M.
- SL-172154 Phase 1 in ovarian cancer well-tolerated with high CD47 occupancy; dose escalation continues to 10mg/kg.
- SL-279252 Phase 1 in solid tumors: one confirmed partial response, stable disease in 12 of 43 patients.
- Shattuck and Takeda mutually terminated collaboration; Shattuck regains full rights to SL-279252 and SL-115154.
- Cash runway sufficient into H2 2024; guidance reduced due to increased SL-172154 clinical and manufacturing costs.

## SEC filing metadata
- accession: 0001680367-21-000052
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036721000052/0001680367-21-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036721000052/sttk-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-21-000052
- JSON: https://secwatch.observer/filing/0001680367-21-000052.json
- Plain text: https://secwatch.observer/filing/0001680367-21-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.